FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2892013022> ?p ?o ?g. }

• W2892013022 endingPage "1220" @default.
• W2892013022 startingPage "1210" @default.
• W2892013022 abstract "Background: The IRIS trial (Insulin Resistance Intervention After Stroke) demonstrated that pioglitazone reduced the risk for both cardiovascular events and diabetes mellitus in insulin-resistant patients. However, concern remains that pioglitazone may increase the risk for heart failure (HF) in susceptible individuals. Methods: In IRIS, patients with insulin resistance but without diabetes mellitus were randomized to pioglitazone or placebo (1:1) within 180 days of an ischemic stroke or transient ischemic attack and followed for ≤5 years. To identify patients at higher HF risk with pioglitazone, we performed a secondary analysis of IRIS participants without HF history at entry. HF episodes were adjudicated by an external review, and treatment effects were analyzed using time-to-event methods. A baseline HF risk score was constructed from a Cox model estimated using stepwise selection. Baseline patient features (individually and summarized in risk score) and postrandomization events were examined as possible modifiers of the effect of pioglitazone. Net cardiovascular benefit was estimated for the composite of stroke, myocardial infarction, and hospitalized HF. Results: Among 3851 patients, the mean age was 63 years, and 65% were male. The 5-year HF risk did not differ by treatment (4.1% pioglitazone, 4.2% placebo). Risk for hospitalized HF was low and not significantly greater in pioglitazone compared with placebo groups (2.9% versus 2.3%, P =0.36). Older age, atrial fibrillation, hypertension, obesity, edema, high C-reactive protein, and smoking were risk factors for HF. However, the effect of pioglitazone did not differ across levels of baseline HF risk (hazard ratio [95% CI] for pioglitazone versus placebo for patients at low, moderate, and high risk: 1.03 [0.61–1.73], 1.10 [0.56–2.15], and 1.08 [0.58–2.01]; interaction P value=0.98). HF risk was increased in patients with versus those without incident myocardial infarction in both groups (pioglitazone: 31.4% versus 2.7%; placebo: 25.7% versus 2.4%; P <0.0001). Edema, dyspnea, and weight gain in the trial did not predict HF hospitalization but led to more study drug dose reduction with a lower mean dose of pioglitazone versus placebo (29±17 mg versus 33±15 mg, P <0.0001). Pioglitazone reduced the composite outcome of stroke, myocardial infarction, or hospitalized HF (hazard ratio, 0.78; P =0.007). Conclusions: In IRIS, with surveillance and dose adjustments, pioglitazone did not increase the risk of HF and conferred net cardiovascular benefit in patients with insulin resistance and cerebrovascular disease. The risk of HF with pioglitazone was not modified by baseline HF risk. The IRIS experience may be instructive for maximizing the net benefit of this therapy. Clinical Trial Registration: URL: https://www.clinicaltrials.gov . Unique identifier: NCT00091949." @default.
• W2892013022 created "2018-09-27" @default.
• W2892013022 creator A5002693861 @default.
• W2892013022 creator A5004980235 @default.
• W2892013022 creator A5016093592 @default.
• W2892013022 creator A5016727208 @default.
• W2892013022 creator A5018584633 @default.
• W2892013022 creator A5037438314 @default.
• W2892013022 creator A5049375797 @default.
• W2892013022 creator A5059445912 @default.
• W2892013022 creator A5061175857 @default.
• W2892013022 creator A5063388307 @default.
• W2892013022 creator A5065063579 @default.
• W2892013022 creator A5073170746 @default.
• W2892013022 creator A5073648006 @default.
• W2892013022 creator A5076194554 @default.
• W2892013022 creator A5090506404 @default.
• W2892013022 date "2018-09-18" @default.
• W2892013022 modified "2023-09-24" @default.
• W2892013022 title "Heart Failure After Ischemic Stroke or Transient Ischemic Attack in Insulin-Resistant Patients Without Diabetes Mellitus Treated With Pioglitazone" @default.
• W2892013022 cites W1480729244 @default.
• W2892013022 cites W1546258268 @default.
• W2892013022 cites W191849520 @default.
• W2892013022 cites W1960825336 @default.
• W2892013022 cites W1980928521 @default.
• W2892013022 cites W1987751736 @default.
• W2892013022 cites W1992644002 @default.
• W2892013022 cites W1996233154 @default.
• W2892013022 cites W2008497553 @default.
• W2892013022 cites W2021976026 @default.
• W2892013022 cites W2026229570 @default.
• W2892013022 cites W2037195555 @default.
• W2892013022 cites W2053853324 @default.
• W2892013022 cites W2075169235 @default.
• W2892013022 cites W2092648747 @default.
• W2892013022 cites W2105719905 @default.
• W2892013022 cites W2112560527 @default.
• W2892013022 cites W2131330057 @default.
• W2892013022 cites W2135729475 @default.
• W2892013022 cites W2159969745 @default.
• W2892013022 cites W2274836352 @default.
• W2892013022 cites W2789496924 @default.
• W2892013022 cites W2892426086 @default.
• W2892013022 cites W4211104669 @default.
• W2892013022 cites W4292856638 @default.
• W2892013022 cites W4293241248 @default.
• W2892013022 doi "https://doi.org/10.1161/circulationaha.118.034763" @default.
• W2892013022 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6202153" @default.
• W2892013022 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29934374" @default.
• W2892013022 hasPublicationYear "2018" @default.
• W2892013022 type Work @default.
• W2892013022 sameAs 2892013022 @default.
• W2892013022 citedByCount "41" @default.
• W2892013022 countsByYear W28920130222018 @default.
• W2892013022 countsByYear W28920130222019 @default.
• W2892013022 countsByYear W28920130222020 @default.
• W2892013022 countsByYear W28920130222021 @default.
• W2892013022 countsByYear W28920130222022 @default.
• W2892013022 countsByYear W28920130222023 @default.
• W2892013022 crossrefType "journal-article" @default.
• W2892013022 hasAuthorship W2892013022A5002693861 @default.
• W2892013022 hasAuthorship W2892013022A5004980235 @default.
• W2892013022 hasAuthorship W2892013022A5016093592 @default.
• W2892013022 hasAuthorship W2892013022A5016727208 @default.
• W2892013022 hasAuthorship W2892013022A5018584633 @default.
• W2892013022 hasAuthorship W2892013022A5037438314 @default.
• W2892013022 hasAuthorship W2892013022A5049375797 @default.
• W2892013022 hasAuthorship W2892013022A5059445912 @default.
• W2892013022 hasAuthorship W2892013022A5061175857 @default.
• W2892013022 hasAuthorship W2892013022A5063388307 @default.
• W2892013022 hasAuthorship W2892013022A5065063579 @default.
• W2892013022 hasAuthorship W2892013022A5073170746 @default.
• W2892013022 hasAuthorship W2892013022A5073648006 @default.
• W2892013022 hasAuthorship W2892013022A5076194554 @default.
• W2892013022 hasAuthorship W2892013022A5090506404 @default.
• W2892013022 hasBestOaLocation W28920130221 @default.
• W2892013022 hasConcept C126322002 @default.
• W2892013022 hasConcept C127413603 @default.
• W2892013022 hasConcept C134018914 @default.
• W2892013022 hasConcept C142724271 @default.
• W2892013022 hasConcept C164705383 @default.
• W2892013022 hasConcept C204787440 @default.
• W2892013022 hasConcept C207103383 @default.
• W2892013022 hasConcept C27081682 @default.
• W2892013022 hasConcept C2777180221 @default.
• W2892013022 hasConcept C2777391703 @default.
• W2892013022 hasConcept C2778198053 @default.
• W2892013022 hasConcept C2778384471 @default.
• W2892013022 hasConcept C2779161974 @default.
• W2892013022 hasConcept C2779306644 @default.
• W2892013022 hasConcept C2780645631 @default.
• W2892013022 hasConcept C44249647 @default.
• W2892013022 hasConcept C500558357 @default.
• W2892013022 hasConcept C50382708 @default.
• W2892013022 hasConcept C555293320 @default.
• W2892013022 hasConcept C71924100 @default.
• W2892013022 hasConcept C78519656 @default.
• W2892013022 hasConceptScore W2892013022C126322002 @default.

• next